BioCryst (BCRX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
450.7M
Gross Profit
438.2M
97.23%
Operating Income
-2.5M
-0.56%
Net Income
-88.9M
-19.72%
EPS (Diluted)
-$0.43
Balance Sheet Metrics
Total Assets
490.4M
Total Liabilities
966.4M
Shareholders Equity
-475.9M
Cash Flow Metrics
Operating Cash Flow
-42.5M
Free Cash Flow
-53.1M
Revenue & Profitability Trend
BioCryst Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 450.7M | 331.4M | 270.8M | 157.2M | 17.8M |
| Cost of Goods Sold | 12.5M | 4.7M | 6.6M | 7.3M | 1.7M |
| Gross Profit | 438.2M | 326.8M | 264.2M | 149.9M | 16.1M |
| Operating Expenses | 440.8M | 430.5M | 412.7M | 327.6M | 190.9M |
| Operating Income | -2.5M | -103.7M | -148.4M | -177.7M | -174.8M |
| Pre-tax Income | -87.0M | -226.2M | -244.4M | -181.8M | -182.8M |
| Income Tax | 1.9M | 310.0K | 2.7M | 2.3M | 0 |
| Net Income | -88.9M | -226.5M | -247.1M | -184.1M | -182.8M |
| EPS (Diluted) | -$0.43 | -$1.18 | -$1.33 | -$1.03 | -$1.09 |
Income Statement Trend
BioCryst Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 422.0M | 496.0M | 516.5M | 566.1M | 323.8M |
| Non-Current Assets | 68.5M | 21.0M | 33.5M | 22.0M | 10.9M |
| Total Assets | 490.4M | 517.0M | 550.0M | 588.2M | 334.7M |
| Liabilities | |||||
| Current Liabilities | 160.4M | 150.0M | 105.5M | 103.7M | 105.7M |
| Non-Current Liabilities | 806.0M | 822.5M | 739.1M | 591.4M | 248.3M |
| Total Liabilities | 966.4M | 972.5M | 844.6M | 695.1M | 354.0M |
| Equity | |||||
| Total Shareholders Equity | -475.9M | -455.5M | -294.6M | -107.0M | -19.3M |
Balance Sheet Composition
BioCryst Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -88.9M | -226.5M | -247.1M | -184.1M | -182.8M |
| Operating Cash Flow | -42.5M | -108.6M | -157.5M | -83.3M | -141.7M |
| Investing Activities | |||||
| Capital Expenditures | -1.1M | -2.2M | -1.4M | -2.4M | -514.0K |
| Investing Cash Flow | 52.6M | -131.5M | -128.2M | 15.8M | -6.9M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -9.2M | 24.1M | 146.3M | 637.8M | 230.9M |
| Free Cash Flow | -53.1M | -97.3M | -163.2M | -144.5M | -135.6M |
Cash Flow Trend
BioCryst Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-23.05
Forward P/E
-247.75
Price to Book
-4.58
Price to Sales
4.12
PEG Ratio
-247.75
Profitability Ratios
Profit Margin
-10.62%
Operating Margin
14.59%
Return on Equity
18.68%
Return on Assets
4.54%
Financial Health
Current Ratio
2.93
Debt to Equity
-1.84
Beta
1.10
Per Share Data
EPS (TTM)
-$0.26
Book Value per Share
-$2.16
Revenue per Share
$2.43
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| bcrx | 2.1B | -23.05 | -4.58 | 18.68% | -10.62% | -1.84 |
| Zoetis | 70.3B | 28.34 | 15.12 | 52.09% | 27.12% | 145.63 |
| Haleon Plc - ADR | 47.2B | 25.01 | 5.88 | 8.95% | 12.84% | 63.41 |
| Regencell Bioscience | 18.5B | - | 1,394.12 | -43.18% | 0.00% | 1.04 |
| Elanco Animal Health | 6.6B | 17.80 | 1.04 | 6.01% | 8.43% | 69.18 |
| Lantheus Holdings | 5.6B | 23.07 | 4.81 | 24.11% | 16.55% | 52.78 |
Financial data is updated regularly. All figures are in the company's reporting currency.